02205nam 22004453 450 991100899490332120231023084510.097892015012269201501226(MiAaPQ)EBC30800221(CKB)28530701300041(Au-PeEL)EBL30800221(Exl-AI)30800221(OCoLC)1406410879(EXLCZ)992853070130004120231023d2023 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierPain Palliation of Bone Metastases Production, Quality Control and Dosimetry of Radiopharmaceuticals1st ed.Vienna :International Atomic Energy Agency,2023.©2023.1 online resource (158 pages)9789201500229 Radionuclide therapy using bone targeting radiopharmaceuticals is an effective palliative care option to reduce pain associated with advanced disease with bone metastases. Over the last 20 years, suitable therapeutic radionuclides are more widely available, meaning that the benefits of pain palliation therapy could reach more patients. This publication provides a broad overview on the current status of radiopharmaceuticals for bone pain palliation. It covers production of radionuclides, identification of bone seeking carrier molecules, preparation of stable complexes, in vitro and in vivo evaluations and dosimetry studies which are part of the development of these radiopharmaceuticals for clinical use. Details on production and quality control of the currently available products, provided here will be of use to scientists involved in the development of these radiopharmaceuticals.Nuclear medicineGenerated by AIRadioisotopes in medical diagnosisGenerated by AINuclear medicineRadioisotopes in medical diagnosisIAEA1594159MiAaPQMiAaPQMiAaPQBOOK9911008994903321Pain Palliation of Bone Metastases4394268UNINA